For over 30 years, Guthrie has been conducting clinical trials in the gastroenterology (GI) department.   

Local access to leading-edge research 

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, Crohn’s disease, ulcerative colitis, reflux disease, hepatitis and many more gastroenterology disease states.

Clinical trials

Clinical trials study new ways to prevent, detect and treat GI disease. If you take part in research, you help advance new investigational medical therapies. Research subjects receive excellent care locally from the Guthrie GI team, while still being able to access cutting-edge therapies offered in large university settings and metropolitan areas. 

GI trials involve preventive measures and investigational treatments and medicines. Your physician can present you with options and help you decide if a clinical trial is right for you.
Most clinical trials offered at Guthrie are phase 2 or phase 3 studies which measure safety and efficacy (whether the investigational treatment benefits a specific group of patients). 

We work with multiple labs, pharmaceutical groups, and biotech companies to offer you the chance to get innovative treatments and novel therapies, and to assist with the future of gastroenterology care. 

Title: * Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07)

** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (Substudy Number: FH-PrwS-07-002)
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Flatiron Health, Inc.
Details (Identifier #): NCT06605404
Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Internal
Details (Identifier #): NCT05694338
Title: A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06568939
Title: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: Amgen Inc.
Details (Identifier #): 06745323
Title: A Phase 3 Randomized, Double-Blind, Active-Controlled
Study of Palazestrant with Ribociclib Versus Letrozole with
Ribociclib for the First-Line Treatment of ER+, HER2
Advanced Breast Cancer (OPERA-02)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT07085767
Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT06016738
Title: A Prospective, Multi-Center, Non-Randomized, SinGle-Arm Study of the BDTM Low ProfILe Vascular Covered Stent in PerIpheral ArTerY Disease (AGILITY)
Department: Vascular Surgery
Diagnosis: Vascular Disease
Principal Investigator:

Marica M.D., Silviu

Sponsors: Becton, Dickinson and Company
Details (Identifier #): NCT06111469
Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION:
THE RESTORATIVE303 STUDY
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator:

Srivatana MD, Ukorn

Sponsors: Vedanta Biosciences, Inc.
Details (Identifier #): NCT06237452
Title: A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Wang, Le

Sponsors: Shanghai Henlius Biotech, Inc.
Details (Identifier #): NCT06532006
Title: A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of
Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus
Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) – LIVIGNO-4
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06236438
Showing 1-10 of 41 Results